ReviewOncology letters2026
Exploration of immunotherapy modalities in stage III unresectable non-small cell lung cancer (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Osteopontin Promotes Lung Cancer Growth through NF-κB-Dependent Upregulation of PD-L1 and Suppression of Anti-Tumor Immunity.Molecular biology reports · 2026Article
- Machine learning models predict survival in unresectable stage III non-small cell lung cancer: Surveillance, Epidemiology, and End Results and Chinese cohort study.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the treatment of stage III unresectable non-small cell lung cancer (NSCLC) has witnessed notable progress due to the application of immune checkpoint inhibitors, which markedly improved patient prognosis. On the basis of pivotal studies such as PACIFIC and GEMSTONE-301, immune consolidation therapy has become the standard regimen. Durvalumab consolidation therapy extended the median progression-free survival (mPFS) from 5.6 to 16.9 months [hazard ratio (HR)=0.55] and the median overall survival from 29.1 to 47.5 months (HR=0.72), thus increasing the 5-year survival rate by ~10%. Sugemalimab demonstrated similar benefits (mPFS, 9.0 vs. 5.8 months; HR=0.64). Currently, immune consolidation therapy serves as the core treatment strategy, whereas induction therapy and treatment de-escalation strategies provide novel options for specific patient populations. The optimization of treatment sequencing is being integrated with dynamic circulating tumor DNA (ctDNA) monitoring. ctDNA clearance after chemoradiotherapy indicates further remission and notably improved survival outcomes. Furthermore, emerging therapeutic modalities such as antibody-drug conjugates and bispecific antibodies are potentially expected to further reshape the treatment landscape in the future. The present review aimed to provide an evidence-based framework for individualized precision treatment for stage III unresectable NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.